Why Materion (MTRN) Is Up 5.5% After Q4 Profit Rebound and 2026 Guidance Update

Why Materion (MTRN) Is Up 5.5% After Q4 Profit Rebound and 2026 Guidance Update

Simply Wall St

Mon, February 16, 2026 at 12:13 PM GMT+9 3 min read

In this article:

MTRN

+0.43%

In February 2026, Materion Corporation reported fourth-quarter 2025 sales of US$489.75 million and a return to quarterly profitability, alongside full-year 2025 sales of US$1.79 billion and net income of US$74.82 million, after recording a loss in the prior-year quarter.
The company coupled this rebound with 2026 earnings guidance of US$6.00–US$6.50 per share and a US$65 million defense-backed beryllium capacity investment, underscoring how its semiconductor and defense exposure is shaping its business mix.
We’ll now examine how Materion’s stronger earnings profile and 2026 guidance range reshape the earlier investment narrative built before these results.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Materion Investment Narrative Recap

To own Materion, you need to believe its specialty materials will keep finding profitable uses in semiconductor, defense and other high value applications, despite exposure to cyclical end markets. The latest results and 2026 earnings guidance support the view that semiconductor and defense remain the key near term catalysts, while customer concentration and any repeat of operational issues in areas like Precision Clad Strip stay front of mind as the most immediate risks.

The most relevant new development is the US$65 million, defense backed beryllium capacity investment, which ties directly into Materion’s defense and aerospace growth pipeline and its mix shift toward higher value engineered materials. This commitment sits alongside the company’s 2026 earnings guidance of US$6.00 to US$6.50 per share, giving investors a clearer line of sight on how expanding beryllium capacity and defense orders could interact with the existing semiconductor demand story.

Yet despite these positives, investors should be aware that any renewed operational setback in Precision Clad Strip could still…

Read the full narrative on Materion (it’s free!)

Materion’s narrative projects $2.1 billion revenue and $355.2 million earnings by 2028. This requires 7.2% yearly revenue growth and a $338.9 million earnings increase from $16.3 million today.

Uncover how Materion’s forecasts yield a $151.33 fair value, a 5% downside to its current price.

Exploring Other Perspectives

MTRN 1-Year Stock Price Chart

Four fair value estimates from the Simply Wall St Community span roughly US$48 to US$222 per share, showing how far apart individual views can be. Set against this, Materion’s reliance on specialty metals and beryllium intensive defense exposure means any supply disruption or cost spike could reshape how you think about its earnings power and risk profile, so it is worth exploring several of these perspectives before deciding how the stock fits your portfolio.

Story Continues  

Explore 4 other fair value estimates on Materion - why the stock might be worth less than half the current price!

Build Your Own Materion Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Materion research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Our free Materion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Materion's overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

Find 53 companies with promising cash flow potential yet trading below their fair value.
AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include MTRN.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin